Literature DB >> 8938217

Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.

N Keldsen1, W Michalski, S M Bentzen, K B Hansen, K Thorling.   

Abstract

A consecutive cohort of patients with NHL was examined to identify the factors predictive of CNS-involvement with Cox's proportional hazards model in a multivariate analysis. Twenty-seven cases of CNS-involvement were found among 498 patients with NHL. Only 3 of 96 patients with low-grade lymphomas had CNS involvement, all occurring after transformation into high-grade lymphoma. In univariate analysis of 402 patients with intermediate or high-grade lymphoma, lymphoblastic histology (including Burkitt's lymphoma), age <35 years, B-symptoms, stage IV disease, testis involvement and bone marrow involvement were found to be statistically significant risk factors. Lymphoblastic histology was found to be strongly correlated to age younger than 35 years. In the multivariate analysis only lymphoblastic histology, stage IV disease and B-symptoms were found to be significantly associated with CNS involvement. It is concluded that CNS prophylaxis should be considered in all patients with lymphoblastic histology and in patients with stage IV B lymphomas other than those of low-grade types.

Entities:  

Mesh:

Year:  1996        PMID: 8938217     DOI: 10.3109/02841869609084002

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  12 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

Review 2.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

Review 3.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

Review 4.  Secondary central nervous system lymphoma.

Authors:  Naoto Tomita; Fumio Kodama; Heiwa Kanamori; Shigeki Motomura; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

5.  Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.

Authors:  Yutaka Shimazu; Kenji Notohara; Yasunori Ueda
Journal:  Int J Hematol       Date:  2009-04-09       Impact factor: 2.490

6.  Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy.

Authors:  Lorenzo Falchi; Marco Gunnellini; Laura Franco; Patrizia Ferrazza; Stefano Ascani; Anna Marina Liberati
Journal:  J Neurooncol       Date:  2009-08-21       Impact factor: 4.130

7.  Antidepressant use and risk of central nervous system metastasis.

Authors:  Megan M Herr; Nimish A Mohile; Edwin van Wijngaarden; Edward B Brown; David Q Rich
Journal:  J Neurooncol       Date:  2016-06-11       Impact factor: 4.130

8.  Leukemias and lymphomas: treatment and prophylaxis of the central nervous system.

Authors:  Janet L Franklin; Jonathan Finlay
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

9.  Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.

Authors:  Katrin Patrij; Marcel Reiser; Luise Wätzel; Hendrik Pels; Annika Kowoll; Ulrich Herrlinger; Andreas Engert; Michael Linnebank; Gabriele Schackert; Marlies Vogt-Schaden; Gerlinde Egerer; Monika Lamprecht; Tracy T Batchelor; Uwe Schlegel; Ingo G H Schmidt-Wolf
Journal:  Ger Med Sci       Date:  2011-05-02

10.  Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma.

Authors:  Talita Maira Bueno da Silveira da Rocha; Fortier Sérgio Costa; Maeva Seo Gomes Pinto; Igor Campos da Silva; Roberto Pinto Paes; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.